[ad_1]
The Russians released their “Sputnik V” vaccine a month ago to vaccinate the general public. Sputnik V, which is funded by a $ 1 billion Russian state fund, has only been in the final phase of clinical trial 3 this week, involving 40,000 people.
The approval process in Russia does not meet international standards. By Western standards, it is taboo to approve vaccines without waiting for all test results. But the Russians want to take off. The vaccine is named after the first Soviet satellites.
Supply contracts with Latin America
The Russians have already agreed with Brazil to produce the vaccine for Latin American countries. The delivery of 32 million cans was agreed with Mexico. The Russians have made a delivery offer to India.
The head of the state RDIF fund, Kirill Dmitriev (45), defends early approval with very strong tests and technologies. For example, they are superior to those of the British-Swedish group Astra Zeneca. Astra Zeneca administered its vaccine to over a thousand test subjects in test phases 1 and 2. The second dose required would have only obtained ten of them. Sputnik V, on the other hand, had been successfully tested twice on 76 test subjects.
Another argument: Sputnik V is based on the same vector technology that has already been tested in Ebola as the Johnson & Johnson vaccine from the US, in which an adenovirus acts as a carrier. But for Sputnik V, not just one, but two proven types of adenovirus would be used.
However, there is no data in the World Health Organization (WHO) Vaccination Candidate List for Sputnik V Phase 2 Trial.
The Chinese also see themselves as winners
The Chinese, in turn, say that four of the eight vaccines on the WHO list that are already in testing phase 3 come from China. The latest testing phase for the vaccines from Sinovac and China National Biotec Group (CNBG) is currently underway in Serbia, Pakistan, Morocco and Argentina, among others.
Although the vaccines have yet to be fully tested, they have already been administered to tens of thousands of people in China under an emergency program.
According to the Reuters news agency, Sinovac has not yet fully published the results of phases 1 and 2 and does not want to publish them.
